Coronary events (MI or cardiac death) · relatively healthy postmenopausal women
Combined continuous hormone therapy (HT) probably leads to higher coronary events (MI or cardiac death) compared with placebo (moderate certainty).
1 finding from 1 review
Stroke · relatively healthy postmenopausal women
Combined continuous hormone therapy (HT) probably leads to higher stroke compared with placebo (moderate certainty).
1 finding from 1 review
Venous thromboembolism · relatively healthy postmenopausal women
Combined continuous hormone therapy (HT) probably leads to higher venous thromboembolism (DVT or PE) compared with placebo (moderate certainty).
1 finding from 1 review
Breast cancer · relatively healthy postmenopausal women
Combined continuous hormone therapy (HT) probably leads to higher breast cancer compared with placebo (moderate certainty).
1 finding from 1 review
Mortality: lung cancer · relatively healthy postmenopausal women
Combined continuous hormone therapy (HT) probably leads to higher death from lung cancer compared with placebo (moderate certainty).
1 finding from 1 review
Gallbladder disease · relatively healthy postmenopausal women
Combined continuous hormone therapy (HT) probably leads to higher gallbladder disease compared with placebo (moderate certainty).
1 finding from 1 review
All clinical fractures · relatively healthy postmenopausal women
Combined continuous hormone therapy (HT) probably leads to lower all clinical fractures compared with placebo (moderate certainty).
1 finding from 1 review
Symptom scores over 2 to 4 menstrual cycles1 · women with PMS
1 finding from 1 review
Withdrawals due to adverse events · women with PMS
It is very uncertain whether oestrogen in combination with progestogen (sequential or continuous) changes withdrawal due to adverse events over 2 to 4 menstrual cycles1 compared with placebo (very low certainty).
1 finding from 1 review
Specific adverse events · women with PMS
It is very uncertain whether oestrogen in combination with progestogen (sequential or continuous) changes specific adverse events over 2 to 4 menstrual cycles1 compared with placebo (very low certainty).
1 finding from 1 review
no estimate extracted
206 participants
Very low
Adverse events for continuous vs standard regimen OCP · women with primary dysmenorrhoea
Combined low‐dose OCP may leads to higher adverse events for continuous vs standard regimen OCP compared with another combined low‐dose OCP (low certainty).
1 finding from 1 review
Pelvic pain · women having endometriosis surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pelvic pain · women having endometriosis surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pelvic pain · women having endometriosis surgery
1 finding from 1 review
Self‐reported pain (dysmenorrhoea) at the end of treatment (continuous data): dysmenorrhoea at 6 months' · women with endometriosis
2 findings from 1 review
Intervention not reported
Moderate dose SSRI versus placebo Luteal or continuous administration · women with premenstrual syndrome
1 finding from 1 review
Intervention not reported
Moderate dose SSRI versus placebo Continuous administration · women with premenstrual syndrome
1 finding from 1 review
Intervention not reported
Low dose SSRI versus placebo Luteal or continuous administration · women with premenstrual syndrome
The intervention probably leads to higher low dose SSRI versus placebo Luteal or continuous administration (moderate certainty).
1 finding from 1 review
Intervention not reported
Mod dose SSRI versus placebo Luteal or continuous administration · women with premenstrual syndrome
The intervention probably leads to higher mod dose SSRI versus placebo Luteal or continuous administration (moderate certainty).
1 finding from 1 review
Intervention not reported
High dose SSRIs versus placebo Continuous administration · women with premenstrual syndrome
The intervention probably leads to higher high dose SSRIs versus placebo Continuous administration (moderate certainty).
1 finding from 1 review